The Functional Footnote Newsletter
Our newsletter contains product information, provides insight into our approach and evaluates the functional food landscape.
Current Issue:
Volume 1, Issue 12, June 2008 (PDF, 89 KB)
What does the future hold for GLPH-1 and PPL-240?
Garrett W. Lindemann, Ph.D.
Chief Executive Officer/Chief Science Officer, Gourmetceuticals LLC
Big Horn, Wyoming USA
Cristina E. Griffin, M.B.A.
Chairman of the Board, Gourmetceuticals LLC, Big Horn, Wyoming USA
Past Issues:
Volume 1, Issue 11, June 2008 (PDF, 78 KB)
PPL-240 Target Markets and Applications
Cristina E. Griffin, M.B.A.
Chairman of the Board, Gourmetceuticals LLC, Big Horn, Wyoming USA
Garrett W. Lindemann, Ph.D.
Chief Executive Officer/Chief Science Officer, Gourmetceuticals LLC
Big Horn, Wyoming USA
Volume 1, Issue 10, May 2008 (PDF, 77 KB)
GLPH-1 Target Markets and Applications
Cristina E. Griffin, M.B.A.
Chairman of the Board, Gourmetceuticals LLC, Big Horn, Wyoming USA
Garrett W. Lindemann, Ph.D.
Chief Executive Officer/Chief Science Officer, Gourmetceuticals LLC
Big Horn, Wyoming USA
Volume 1, Issue 9, April 2008 (PDF, 185 KB)
What are the presentations of GLPH-1 and PPL-240 in veterinary, functional foods and cosmeceuticals?
Garrett W. Lindemann, Ph.D.
Chief Executive Officer/Chief Science Officer, Gourmetceuticals LLC
Big Horn, Wyoming USA
Cristina E. Griffin, M.B.A.
Chairman of the Board, Gourmetceuticals LLC, Big Horn, Wyoming USA
Volume 1, Issue 8, March 2008 (PDF, 60 KB)
What is the regulatory and patent status of GLPH-1 and PPL-240?
Garrett W. Lindemann, Ph.D.
Chief Executive Officer/Chief Science Officer, Gourmetceuticals LLC
Big Horn, Wyoming USA
Volume 1, Issue 7, February 2008 (PDF, 81 KB)
What is the industrial process and GMP quality control of PPL-240?
Marta Domínguez, Ph.D.
Technical Director, Industrial Farmaceutica Cantabria S.A., Madrid, Spain
Antonio Guerrero, Ph.D.
Head of Quality Assurance, Industrial Farmaceutica Cantabria S.A., Madrid, Spain
Volume 1, Issue 6, January 2008 (PDF, 89 KB)
What is the industrial process and GMP quality control of GLPH-1?
Marta Domínguez, Ph.D.
Technical Director, Industrial Farmaceutica Cantabria S.A., Madrid, Spain
Antonio Guerrero, Ph.D.
Head of Quality Assurance, Industrial Farmaceutica Cantabria S.A., Madrid, Spain
Volume 1, Issue 5, December 2007 (PDF, 83 KB)
What are the activities of PPL-240?
Eduardo Reyes, Ph.D.
Assistant Professor of Immunology, Alcala University, Madrid, Spain
With input from Salvador Gonzalez, M.D., Ph.D.
Faculty of Dermatology Service, Memorial Sloan-Kettering Cancer Center, New York, New York USA
Volume 1, Issue 4, November 2007 (PDF, 86 KB)
What are the activities of GLPH-1?
Garrett W. Lindemann, Ph.D.
Chief Executive Officer/Chief Science Officer, Gourmetceuticals LLC
Big Horn, Wyoming USA
Jose Luis Alonso, Ph.D.
Product Manager, Industrial Farmaceutica Cantabria S.A., Madrid, Spain
Volume 1, Issue 3, October 2007 (PDF, 130 KB)
What is PPL-240?
Eduardo Reyes, Ph.D.
Assistant Professor of Immunology, Alcala University, Madrid, Spain
Antonio Guerrero, Ph.D.
Head of Quality Assurance, Industrial Farmaceutica Cantabria S.A., Madrid, Spain
With input from Salvador Gonzalez, M.D., Ph.D.
Faculty of Dermatology Service, Memorial Sloan-Kettering Cancer Center, New York, New York USA
Volume 1, Issue 2, September 2007 (PDF, 92 KB)
What is GLPH-1?
Eduardo Reyes, Ph.D.
Assistant Professor of Immunology, Alcala University, Madrid, Spain
Jose Luis Alonso, Ph.D.
Product Manager, Industrial Farmaceutica Cantabria S.A., Madrid, Spain
Antonio Guerrero, Ph.D.
Head of Quality Assurance, Industrial Farmaceutica Cantabria S.A., Madrid, Spain
Volume 1, Issue 1, August 2007 (PDF, 67 KB)
Welcome Letter
Garrett W. Lindemann, Ph.D.
Chief Executive Officer/Chief Science Officer, Gourmetceuticals LLC
Big Horn, Wyoming USA